Briacell Therapeutics
BCTX
13 hedge funds and large institutions have $94.1K invested in Briacell Therapeutics in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 14 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
0.06% more ownership
Funds ownership: 0.01% → 0.07% (+0.06%)
48% less funds holding
Funds holding: 25 → 13 (-12)
75% less capital invested
Capital invested by funds: $379K → $94.1K (-$285K)
86% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$78.4K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$4.77K |
| 3 |
Morgan Stanley
New York
|
+$2.29K |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$2.05K |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
+$1.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vontobel Holding
Zurich,
Switzerland
|
-$62.1K |
| 2 |
CF
Cantor Fitzgerald
New York
|
-$31.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$28.6K |
| 4 |
OBWG
Onyx Bridge Wealth Group
Tarrytown,
New York
|
-$28.3K |
| 5 |
VF
Virtu Financial
New York
|
-$27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wolverine Trading
Chicago,
Illinois
| – | -$7.73K | -90 | Closed |
|
27
Cambridge Investment Research Advisors
Fairfield,
Iowa
| – | -$6K | -75 | Closed |
|
28
Bank of America
Charlotte,
North Carolina
| – | -$8 | – | – |
|
|
FIA
29
FNY Investment Advisers
New York
| – | +$477 | +10 | +100% |
|
BCTX Hedge Fund Activity: Q1 2025 in Review
13 of the 7,460 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q1 2025, worth a combined $94.1K — down 75% from $379K a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of BCTX and 2 opened new positions — a net loss of 12 holders — while 1 trimmed existing stakes and 6 added.
The largest buyer was UBS Group, adding an estimated $78.4K. The largest seller was Vontobel Holding, exiting entirely with an estimated $62.1K sold.
- 13 institutional investors held Briacell Therapeutics (BCTX) as of Q1 2025, down from 25 in Q4 2024.
- Funds reported $94.1K of Briacell Therapeutics stock for Q1 2025, down 75% quarter-over-quarter.
- 2 funds opened new Briacell Therapeutics positions in Q1 2025 and 14 closed out, a net change of -12 holders.
- The largest Briacell Therapeutics buyer in Q1 2025 was UBS Group, an estimated $78.4K added.
- The largest Briacell Therapeutics seller in Q1 2025 was Vontobel Holding, an estimated $62.1K sold.
Based on aggregated 13F filings for Q1 2025.